Drugs / T cell vaccination
T cell vaccination
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00220428 | Jul 1998 → Dec 2007 | multiple sclerosis | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00407836 | Nov 2006 → Nov 2008 | HIV infectious disease | Soroka University Medical Center | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT01448252 Comparator | May 2002 → Sep 2008 | multiple sclerosis | Hadassah Medical Organization | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | T-cell vaccination | “T-cell vaccination against CD4 autoimmunity is feasible and safe.” PMID 15567094 ↗ Dec 2004 |
| Known as | T-cell vaccine | “This study is an extended clinical trial of the one initiated and reported in the Journal of Clinical Virology 2004;31S:S48-54. Thirteen HIV-1 patients (eight subtype B and...” PMID 15755585 ↗ Mar 2005 |
| Known as | TCV | “T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation.” PMID 23272061 ↗ Dec 20121“T-cell vaccination (TCV) may decrease such autoimmunity and elevate CD4 T-cell numbers.” PMID 15755585 ↗ Mar 2005 |
| Modality | Cell therapy | “irradiated autologous encephalitogenic myelin peptides (EMP) specific T-cell lines or clones” NCT00220428 ↗ |
| Route | Subcutaneous | “given subcutaneously every three months during the first year of the trial.” NCT00407836 ↗ |